Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yamanaka, Hisashi | - |
dc.contributor.author | Nagaoka, Shouhei | - |
dc.contributor.author | Lee, Soo-Kon | - |
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Kasama, Tsuyoshi | - |
dc.contributor.author | Kobayashi, Hitomi | - |
dc.contributor.author | Nishioka, Yuichi | - |
dc.contributor.author | Ueki, Yukitaka | - |
dc.contributor.author | Seto, Yohei | - |
dc.contributor.author | Nishinarita, Makoto | - |
dc.contributor.author | Tamura, Naoto | - |
dc.contributor.author | Kimura, Noriko | - |
dc.contributor.author | Saito, Kazuyoshi | - |
dc.contributor.author | Tomita, Tetsuya | - |
dc.contributor.author | Nawata, Yasushi | - |
dc.contributor.author | Suzuki, Sadahiro | - |
dc.contributor.author | Ishigatsubo, Yoshiaki | - |
dc.contributor.author | Munakata, Yasuhiko | - |
dc.contributor.author | Makino, Yuichi | - |
dc.contributor.author | Inoue, Eisuke | - |
dc.contributor.author | Tanaka, Yoshiya | - |
dc.contributor.author | Takeuchi, Tsutomu | - |
dc.date.accessioned | 2021-07-30T05:28:04Z | - |
dc.date.available | 2021-07-30T05:28:04Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 1439-7595 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4958 | - |
dc.description.abstract | Objectives: To investigate the efficacy and safety of etanercept (ETN) in patients with rheumatoid arthritis (RA) with moderate disease activity and the possibility to discontinue ETN after achieving remission. Methods: Multicenter, randomized, and open-label study was conducted in Japan and Korea. RA patients (disease duration <5 years) with moderate disease activity despite methotrexate (MTX) treatment were allocated to either MTX or ETN + MTX (Period 1) for 12 months. Patients who achieved sustained remission defined as DAS28 <2.6 at both 6 and 12 months in the ETN + MTX group, were randomized to either continue or discontinue ETN for 12 months (Period 2). Results: A total of 222 patients were enrolled in Period 1 and clinical remission was achieved in 106/ 157 (67.5%) and 5/ 28 (17.9%) patients in the ETN + MTX and MTX groups, respectively. In Period 2, sixty-seven patients were randomized and finally 28/ 32 (87.5%) and 15/ 28 (53.6%) patients who continued or discontinued ETN maintained clinical remission. Baseline disease activity and the presence of comorbid diseases influenced the maintenance of remission after ETN discontinuation. Conclusions: ETN + MTX was efficient for RA patients with moderate disease activity into remission. After achieving sustained remission, a half of the patients who discontinued ETN could maintain remission for 1 year. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, Sang-Cheol | - |
dc.identifier.doi | 10.3109/14397595.2015.1123349 | - |
dc.identifier.scopusid | 2-s2.0-84951265153 | - |
dc.identifier.wosid | 000393120600005 | - |
dc.identifier.bibliographicCitation | MODERN RHEUMATOLOGY, v.26, no.5, pp.651 - 661 | - |
dc.relation.isPartOf | MODERN RHEUMATOLOGY | - |
dc.citation.title | MODERN RHEUMATOLOGY | - |
dc.citation.volume | 26 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 651 | - |
dc.citation.endPage | 661 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | HEALTH-ASSESSMENT QUESTIONNAIRE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | BIOLOGICS | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | ADALIMUMAB | - |
dc.subject.keywordPlus | RA | - |
dc.subject.keywordAuthor | Clinical trial | - |
dc.subject.keywordAuthor | Discontinuation | - |
dc.subject.keywordAuthor | Etanercept | - |
dc.subject.keywordAuthor | Remission | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.identifier.url | https://academic.oup.com/mr/article/26/5/651/6296397 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.